Market data

Select a section

Sareum Holdings

(SAR)
Sector: Pharmaceuticals & Biotechnology
28.67p
2.17p 8.18
Last updated: 13:12:28

Company News Headlines

Date Time Headline Source
29/10/2024 07:00 Final Results for the Year Ended 30 June 2024 RNS
23/10/2024 07:00 Notice of Final Results and Investor Presentation RNS
21/10/2024 07:00 Further Subscription to raise £1,000,000 RNS
11/10/2024 07:00 Subscription to raise £2,364,000 RNS
16/09/2024 07:00 Patent Allowance in China RNS
02/09/2024 07:00 US patent allowance RNS
10/07/2024 07:00 Management Changes RNS
01/07/2024 07:00 Positive Data from SDC-1801 Phase 1 Clinical Trial RNS
30/05/2024 07:00 Appointment of Sole Broker RNS
07/05/2024 14:10 Exercise of Warrants RNS
23/04/2024 07:00 Final Issue of RiverFort Subscription Shares RNS
19/04/2024 11:35 Issue of RiverFort Subscription Shares RNS
15/04/2024 15:28 Issue of RiverFort Subscription Shares RNS
09/04/2024 16:00 Issue of RiverFort Subscription Shares RNS
04/04/2024 14:38 Completion of Equity Fundraise RNS
02/04/2024 16:51 Result of WRAP Retail Offer RNS
02/04/2024 07:00 Increase in size of WRAP Retail Offer RNS
28/03/2024 07:02 WRAP Retail Offer RNS
28/03/2024 07:01 Equity Fundraise RNS
28/03/2024 07:00 Sareum Half-Year Report RNS
15/03/2024 07:00 New Patent Allowance RNS
12/03/2024 13:30 Notice of Interim Results and Trading Update RNS
15/02/2024 07:00 Update on SDC-1801 Clinical Trial Progress RNS
02/01/2024 07:00 Development and commercialisation licence SRA737 RNS
14/12/2023 15:35 Results of AGM RNS
14/12/2023 07:00 Annual General Meeting Statement RNS
23/11/2023 07:00 Drawdown of Equity Prepayment Facility RNS
21/11/2023 07:00 Notice of AGM, Annual Report and Accounts RNS
09/11/2023 07:00 Initiation of food effects study for SDC-1801 RNS
08/11/2023 15:03 Director Dealings RNS
03/11/2023 07:05 Sareum enhances SDC-1801 patent protection RNS
02/11/2023 14:48 Exercise of Share Options and Director Dealings RNS
09/10/2023 07:00 Final Results for the Year Ended 30 June 2023 RNS
03/10/2023 07:00 Notice of Results and Investor Presentation RNS
06/09/2023 07:00 Director's Dealing RNS
05/09/2023 07:00 Director Dealing RNS
04/09/2023 07:00 Dosing of first subjects in MAD Phase 1a trial RNS
16/08/2023 07:00 Update on financial and operational progress RNS
03/08/2023 07:00 Equity Prepayment Facility of up to £5 million RNS
26/06/2023 07:00 Sareum Announces Two New Granted Patents RNS
06/06/2023 07:00 Dosing commences in Phase 1a trial of SDC-801 RNS
18/05/2023 07:00 Phase 1a clinical trial for SDC-1801 RNS
05/05/2023 09:20 Approval to initiate Phase 1 clinical trial RNS
22/03/2023 07:00 Half-Year Report RNS
15/03/2023 07:01 Update on SDC-1801 RNS
15/03/2023 07:00 Notice of Half-Year Results RNS
06/03/2023 07:00 Update on SRA737 RNS
29/12/2022 15:14 Director/PDMR Shareholding RNS
16/12/2022 15:29 Results of AGM RNS
16/12/2022 07:00 AGM Statement RNS

Market data

Select a section